Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
Johanna Friedl-Naderer, the Chief Commercial Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold shares in the company. According to a filing with the Securities and Exchange Commission, Friedl-Naderer sold 146 shares of common stock on June 5, 2025, at a weighted average price of $13.35 per share. The stock, which currently trades at $14.70, has seen significant volatility this year with a 52-week range of $6.36 to $47.45. InvestingPro analysis indicates the company is currently fairly valued, with analysts maintaining a strong buy consensus. This transaction, valued at approximately $1,949, was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units.
Following the sale, Friedl-Naderer retains ownership of 95,911 shares in Dyne Therapeutics, which includes 91,476 unvested restricted stock units. The transaction was part of a pre-arranged trading plan under Rule 10b5-1, ensuring it was not a discretionary trade.
In other recent news, Dyne Therapeutics has shared significant developments in its ongoing clinical trials and regulatory engagements. The company recently updated its Phase 1/2 ACHIEVE trial for DYNE-101, revealing robust splicing correction and functional improvements, with results from the expansion cohort expected in the first half of 2026. Additionally, Dyne’s DYNE-251 for Duchenne muscular dystrophy (DMD) received orphan drug designation from the European Commission, promising benefits like reduced fees and potential market exclusivity. The DELIVER trial for DYNE-251 has completed enrollment, with results anticipated by late 2025. Analysts from Oppenheimer, Evercore ISI, and Stifel have weighed in on Dyne’s prospects, with Oppenheimer and Evercore ISI assigning an Outperform rating and Stifel maintaining a Buy rating. Evercore ISI set a $46 price target, highlighting optimism in Dyne’s DM1 and DMD programs, while Stifel set a higher target of $66 following discussions with company executives. H.C. Wainwright adjusted its price target to $38, emphasizing Dyne’s commitment to securing accelerated approval for DYNE-101. These developments reflect the company’s strategic efforts in advancing its clinical programs and navigating regulatory pathways.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.